For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's ...
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot ... the diabetes shot that’s often taken ...
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...